Piper Jaffray Companies reissued their overweight rating on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Monday. Piper Jaffray Companies also issued estimates for GW Pharmaceuticals PLC-‘s Q4 2018 earnings at ($2.27) EPS, FY2018 earnings at ($9.08) EPS, Q1 2019 earnings at ($2.01) EPS, Q2 2019 earnings at ($1.86) EPS, Q3 2019 earnings at ($1.40) EPS, Q4 2019 earnings at ($1.32) EPS, FY2019 earnings at ($6.60) EPS, FY2020 earnings at $1.56 EPS, FY2021 earnings at $7.91 EPS and FY2022 earnings at $12.64 EPS.
GWPH has been the subject of several other reports. Cantor Fitzgerald set a $211.00 price objective on GW Pharmaceuticals PLC- and gave the company a buy rating in a report on Thursday, September 27th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a hold rating to a strong-buy rating and set a $168.00 price objective for the company in a report on Wednesday, October 10th. BidaskClub raised GW Pharmaceuticals PLC- from a hold rating to a buy rating in a report on Saturday, September 22nd. ValuEngine lowered GW Pharmaceuticals PLC- from a buy rating to a hold rating in a report on Thursday, August 2nd. Finally, Bank of America reaffirmed a buy rating and issued a $197.00 price target (up from $181.00) on shares of GW Pharmaceuticals PLC- in a report on Friday, September 28th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $184.13.
NASDAQ GWPH traded down $1.59 on Monday, hitting $149.14. 123,421 shares of the stock traded hands, compared to its average volume of 532,287. GW Pharmaceuticals PLC- has a 12 month low of $105.12 and a 12 month high of $179.65. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of -21.46 and a beta of 2.25. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01.
Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its holdings in shares of GW Pharmaceuticals PLC- by 4,345.8% in the first quarter. JPMorgan Chase & Co. now owns 20,984 shares of the biopharmaceutical company’s stock worth $2,364,000 after buying an additional 20,512 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of GW Pharmaceuticals PLC- by 25.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,057 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 619 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of GW Pharmaceuticals PLC- by 9.0% during the first quarter. LPL Financial LLC now owns 8,418 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 692 shares during the last quarter. Royal Bank of Canada raised its holdings in GW Pharmaceuticals PLC- by 29.9% in the 1st quarter. Royal Bank of Canada now owns 7,096 shares of the biopharmaceutical company’s stock worth $800,000 after acquiring an additional 1,632 shares during the last quarter. Finally, Suntrust Banks Inc. purchased a new position in GW Pharmaceuticals PLC- in the 1st quarter worth approximately $227,000. Institutional investors own 70.02% of the company’s stock.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Recommended Story: What is a Tariff?
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.